Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma

Clinical Nuclear Medicine

Volumn 37, Issue 7, 2012, Pages 656-662

  Nakatani, Koya ^a   Nakamoto, Yuji ^a   Watanabe, Kenichiro ^a   Saga, Tsuneo ^b   Higashi, Tatsuya ^c   Togashi, Kaori ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c Shiga Medical Center for Adults   (Japan)

Author keywords

F 18 FDG; lymphoma; non Hodgkin; pediatrics; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CONVENTIONAL IMAGING MODALITY; DEATH; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; LARGE CELL LYMPHOMA; MALE; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; REMISSION INDUCTION; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84862553236     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318238f72b     Document Type: Article

References (25)

1. Toma P, Granata C, Rossi A, et al. Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. Radiographics. 2007;27: 1335-1354.
2. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin-s lymphoma in childhood. N Engl J Med. 1996;334:1238-1248.
3. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
4. Miller E, Metser U, Avrahami G, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr. 2006;30:689-694.
5. Montravers F, McNamara D, Landman-Parker J, et al. E(18)F̂FDG in childhood lymphoma: Clinical utility and impact on management. Eur J Nucl Med Mol Imaging. 2002;29:1155-1165.
6. Depas G, De Barsy C, Jerusalem G, et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging. 2005;32:31-38.
7. Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol. 2006;36:524-531.
8. Riad R, Omar W, Kotb M, et al. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:319-329.
9. Glaser SL, Hsu JL. Hodgkin-s disease in Asians: Incidence patterns and risk factors in population-based data. Leuk Res. 2002;26:261-269.
10. Furth C, Steffen IG, Amthauer H, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin-s lymphoma: Analysis of a prospective multicenter trial. J Clin Oncol. 2009;27:4385-4391.
11. Amthauer H, Furth C, Denecke T, et al. FDG-PET in 10 children with non-Hodgkin-s lymphoma: Initial experience in staging and follow-up. Klin Padiatr. 2005;217:327-333.
12. Shankar A, Fiumara F, Pinkerton R. Role of FDG PET in the management of childhood lymphomasYcase proven or is the jury still out? Eur J Cancer. 2008;44:663-673.
13. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin-s lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332-339.
14. Stauss J, Franzius C, Pfluger T, et al. Guidelines for 18F-FDG PETand PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35: 1581-1588.
15. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
16. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. 2007;7:10-18.
17. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin-s lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol. 2009;27:1906-1914.
18. Riad R, Omar W, Sidhom I, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt-s lymphoma. Nucl Med Commun. 2010;31:232-238.
19. Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer. 2005;44:70-76.
20. Mody RJ, Bui C, Hutchinson RJ, et al. Comparison of (18)F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma. 2007;48:699-707.
21. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol. 2006;28:711-714.
22. Meany HJ, Gidvani VK, Minniti CP. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer. 2007;48:399-402.
23. Kabickova E, Sumerauer D, Cumlivska E, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin-s disease. Eur J Nucl Med Mol Imaging. 2006;33: 1025-1031.
24. Pinkerton R. Continuing challenges in childhood non-Hodgkin-s lymphoma. Br J Haematol. 2005;130:480-488.
25. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the riskadapted therapy of lymphoma. J Nucl Med. 2007;48(suppl 1):19SY27S.